Skip to main content
Clinical Trials/JPRN-jRCTs052210188
JPRN-jRCTs052210188
Active, not recruiting
Phase 2

A phase II study Investigating the efficacy and safety of polyglycolic acid sheet for the prevention of infectious complication after laparoscopic surgery for gastric cancer

Obama Kazutaka0 sites210 target enrollmentMarch 8, 2022

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Intraperitoneal infectious complications
Sponsor
Obama Kazutaka
Enrollment
210
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 8, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Obama Kazutaka

Eligibility Criteria

Inclusion Criteria

  • 1\)Pathologically diagnosed gastric adenocarcinoma
  • 2\)Laparoscopic/Robotic distal gastrectomy or total gastrectomy was performed
  • 3\)Clinical Stage I \- III
  • 4\)Aged 18 \- 85 years
  • 5\)Male and Female
  • 6\)ECOG Performance Status (PS) 0\-1
  • 7\)Written informed consent was obtained

Exclusion Criteria

  • 1\)Distant metastasis, invasion to other organs, or spread to esophagus
  • 2\)Neoadjuvant chemotherapy
  • 3\)Past history of irradiation to upper abdomen
  • 4\)Past history of upper abdominal surgery
  • 5\)Combined surgery for other diseases other than cholecystectomy
  • 6\)Severe infectious disease or other comorbidities
  • 7\)Sever drug allergy
  • 8\)Immune\-suppressing drug or steroid use
  • 9\)Peritoneal dialysis or Hemodialysis
  • 10\)Multiple antiplatelet/ anticoagulant drug use or warfarin use

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
PGL5001 Proof of Concept study in inflammatory endometriosis
EUCTR2012-001219-22-PLPregLem S.A.
Recruiting
Phase 2
A Phase II Study to Investigate the Efficacy and Safety of Oral intake of Anamorelin in Patients After Total GastrectomyAfter Total Gastrectomy
JPRN-jRCTs041230012Bando Etsuro65
Active, not recruiting
Phase 1
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000015841Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-005115-41-HUTransgene S.A.39
Active, not recruiting
Phase 1
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-005115-41-BETransgene S.A.44
Active, not recruiting
Phase 1
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-005115-41-DKTransgene S.A.39